Indrayani Biotech Limited (BOM:526445)
India
· Delayed Price · Currency is INR 17.64
-0.36 (-2.00%)
At close: May 6, 2025
Indrayani Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,662 | 1,629 | 615.72 | 210.88 | 498.97 | Upgrade
|
| Other Revenue | - | 0.02 | 0.11 | 1.03 | - | Upgrade
|
| Revenue | 1,662 | 1,629 | 615.82 | 211.91 | 498.97 | Upgrade
|
| Revenue Growth (YoY) | 2.02% | 164.57% | 190.60% | -57.53% | - | Upgrade
|
| Cost of Revenue | 984.08 | 1,039 | 414.11 | 160.71 | 329.37 | Upgrade
|
| Gross Profit | 678.18 | 590.2 | 201.72 | 51.2 | 169.6 | Upgrade
|
| Selling, General & Admin | 258.36 | 252.87 | 107.75 | 66.86 | 120 | Upgrade
|
| Other Operating Expenses | 175.23 | 157.06 | 25.2 | 32.81 | 21.84 | Upgrade
|
| Operating Expenses | 471.59 | 443.41 | 139.54 | 104.25 | 151.99 | Upgrade
|
| Operating Income | 206.58 | 146.79 | 62.17 | -53.05 | 17.61 | Upgrade
|
| Interest Expense | -98.83 | -49.99 | -18.26 | -19.08 | -11.51 | Upgrade
|
| Interest & Investment Income | 1.57 | 26.09 | 1.14 | 1.59 | 0.69 | Upgrade
|
| Earnings From Equity Investments | - | - | - | 0.03 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.42 | 4.65 | -0.54 | -0.54 | 1.28 | Upgrade
|
| EBT Excluding Unusual Items | 109.74 | 127.54 | 44.52 | -71.05 | 8.07 | Upgrade
|
| Asset Writedown | - | -5 | - | - | - | Upgrade
|
| Other Unusual Items | - | 0.52 | - | -41.1 | - | Upgrade
|
| Pretax Income | 109.74 | 123.06 | 44.52 | -112.14 | 8.07 | Upgrade
|
| Income Tax Expense | 5.52 | 3.75 | 0.12 | - | - | Upgrade
|
| Earnings From Continuing Operations | 104.23 | 119.31 | 44.4 | -112.14 | 8.07 | Upgrade
|
| Minority Interest in Earnings | -40.58 | -31.94 | -0.46 | - | - | Upgrade
|
| Net Income | 63.65 | 87.37 | 43.93 | -112.14 | 8.07 | Upgrade
|
| Net Income to Common | 63.65 | 87.37 | 43.93 | -112.14 | 8.07 | Upgrade
|
| Net Income Growth | -27.15% | 98.87% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 39 | 34 | 34 | 36 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 43 | 34 | 36 | 4 | Upgrade
|
| Shares Change (YoY) | -10.44% | 27.02% | -3.86% | 878.95% | 1.21% | Upgrade
|
| EPS (Basic) | 1.63 | 2.55 | 1.28 | -3.15 | 2.22 | Upgrade
|
| EPS (Diluted) | 1.63 | 2.01 | 1.28 | -3.15 | 2.22 | Upgrade
|
| EPS Growth | -18.91% | 57.03% | - | - | - | Upgrade
|
| Free Cash Flow | -468.41 | -53.4 | 29.22 | -4.4 | - | Upgrade
|
| Free Cash Flow Per Share | -12.03 | -1.23 | 0.85 | -0.12 | - | Upgrade
|
| Gross Margin | 40.80% | 36.22% | 32.76% | 24.16% | 33.99% | Upgrade
|
| Operating Margin | 12.43% | 9.01% | 10.10% | -25.04% | 3.53% | Upgrade
|
| Profit Margin | 3.83% | 5.36% | 7.13% | -52.92% | 1.62% | Upgrade
|
| Free Cash Flow Margin | -28.18% | -3.28% | 4.75% | -2.08% | - | Upgrade
|
| EBITDA | 244.64 | 180.26 | 68.77 | -48.47 | 27.76 | Upgrade
|
| EBITDA Margin | 14.72% | 11.06% | 11.17% | -22.87% | 5.56% | Upgrade
|
| D&A For EBITDA | 38.05 | 33.47 | 6.59 | 4.58 | 10.14 | Upgrade
|
| EBIT | 206.58 | 146.79 | 62.17 | -53.05 | 17.61 | Upgrade
|
| EBIT Margin | 12.43% | 9.01% | 10.10% | -25.04% | 3.53% | Upgrade
|
| Effective Tax Rate | 5.03% | 3.05% | 0.28% | - | - | Upgrade
|
| Revenue as Reported | 1,674 | 1,674 | 617.93 | 213.53 | 500.94 | Upgrade
|
| Advertising Expenses | 8.19 | 8.89 | 1.65 | 3.16 | 0.01 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.